[5-(difluoromethyl)-1H-pyrazol-3-yl]-[7-(3-methoxyphenyl)-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]methanone
C18H17F2N5O2 — CID 165420842
Data last refreshed: (MolForge compound catalog, from PubChem)
About [5-(difluoromethyl)-1H-pyrazol-3-yl]-[7-(3-methoxyphenyl)-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]methanone
[5-(difluoromethyl)-1H-pyrazol-3-yl]-[7-(3-methoxyphenyl)-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]methanone (PubChem CID 165420842) has the molecular formula C18H17F2N5O2 and a molecular weight of 373.36 g/mol. Its IUPAC name is [5-(difluoromethyl)-1H-pyrazol-3-yl]-[7-(3-methoxyphenyl)-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]methanone.
Molecular Properties
| Compound Name | [5-(difluoromethyl)-1H-pyrazol-3-yl]-[7-(3-methoxyphenyl)-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]methanone |
|---|---|
| PubChem CID | 165420842 |
| Molecular Formula | C18H17F2N5O2 |
| Molecular Weight | 373.36 g/mol |
| Exact Mass | 373.14 |
| IUPAC Name | [5-(difluoromethyl)-1H-pyrazol-3-yl]-[7-(3-methoxyphenyl)-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]methanone |
| SMILES | COc1cccc(C2CN(C(=O)c3cc(C(F)F)[nH]n3)Cc3[nH]cnc32)c1 |
| InChI | InChI=1S/C18H17F2N5O2/c1-27-11-4-2-3-10(5-11)12-7-25(8-15-16(12)22-9-21-15)18(26)14-6-13(17(19)20)23-24-14/h2-6,9,12,17H,7-8H2,1H3,(H,21,22)(H,23,24) |
| InChIKey | YFQDNEYXDLNNGX-UHFFFAOYSA-N |
| XLogP | 2.87 |
| TPSA | 86.90 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 373.36 |
| LogP ≤ 5 | 2.87 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 165420842 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.